title: Reply: To PMID 24530602.
authors.affiliation: Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
authors.forename: Miguel
authors.initials: M
authors.lastname: Regueiro
authors.affiliation: Research Center, College of Nursing, University of South Florida, Tampa, Florida.
authors.forename: Kevin E
authors.initials: KE
authors.lastname: Kip
authors.affiliation: Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
authors.forename: Leonard
authors.initials: L
authors.lastname: Baidoo
authors.affiliation: Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
authors.forename: Jason M
authors.initials: JM
authors.lastname: Swoger
authors.affiliation: Division of Gastrointestinal Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Schraut
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003424:Crohn Disease / Q000517:prevention & control* / Q000601:surgery*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069285:Infliximab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069285:Infliximab; D000068879:Adalimumab